David Bailey Purchases 32,134 Shares of KindlyMD (NASDAQ:NAKA) Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 32,134 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were acquired at an average price of $5.59 per share, for a total transaction of $179,629.06. Following the completion of the acquisition, the chief executive officer directly owned 32,134 shares of the company’s stock, valued at $179,629.06. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

KindlyMD Trading Up 12.1%

NAKA stock opened at $7.06 on Friday. The stock’s fifty day simple moving average is $4.54 and its two-hundred day simple moving average is $7.24. KindlyMD, Inc. has a 1-year low of $3.33 and a 1-year high of $422.40. The stock has a market cap of $126.37 million, a P/E ratio of -0.20 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA) last announced its earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The business had revenue of $35.87 million for the quarter. As a group, analysts forecast that KindlyMD, Inc. will post -11.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NAKA has been the subject of a number of research reports. TD Cowen increased their target price on shares of KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, KindlyMD currently has an average rating of “Hold” and an average price target of $22.33.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock valued at $484,000 after acquiring an additional 8,386 shares during the last quarter. Osaic Holdings Inc. purchased a new stake in shares of KindlyMD in the 2nd quarter valued at $215,000. Victory Capital Management Inc. purchased a new stake in shares of KindlyMD in the 3rd quarter valued at $1,007,000. UBS Group AG grew its holdings in shares of KindlyMD by 5,244.3% during the 3rd quarter. UBS Group AG now owns 387,142 shares of the company’s stock valued at $9,655,000 after purchasing an additional 379,898 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new position in shares of KindlyMD during the 3rd quarter valued at $5,460,000.

KindlyMD News Roundup

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.